» Articles » PMID: 18795102

Fibrotic Myofibroblasts Manifest Genome-wide Derangements of Translational Control

Overview
Journal PLoS One
Date 2008 Sep 17
PMID 18795102
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: As a group, fibroproliferative disorders of the lung, liver, kidney, heart, vasculature and integument are common, progressive and refractory to therapy. They can emerge following toxic insults, but are frequently idiopathic. Their enigmatic propensity to resist therapy and progress to organ failure has focused attention on the myofibroblast-the primary effector of the fibroproliferative response. We have recently shown that aberrant beta 1 integrin signaling in fibrotic fibroblasts results in defective PTEN function, unrestrained Akt signaling and subsequent activation of the translation initiation machinery. How this pathological integrin signaling alters the gene expression pathway has not been elucidated.

Results: Using a systems approach to study this question in a prototype fibrotic disease, Idiopathic Pulmonary Fibrosis (IPF); here we show organized changes in the gene expression pathway of primary lung myofibroblasts that persist for up to 9 sub-cultivations in vitro. When comparing IPF and control myofibroblasts in a 3-dimensional type I collagen matrix, more genes differed at the level of ribosome recruitment than at the level of transcript abundance, indicating pathological translational control as a major characteristic of IPF myofibroblasts. To determine the effect of matrix state on translational control, myofibroblasts were permitted to contract the matrix. Ribosome recruitment in control myofibroblasts was relatively stable. In contrast, IPF cells manifested large alterations in the ribosome recruitment pattern. Pathological studies suggest an epithelial origin for IPF myofibroblasts through the epithelial to mesenchymal transition (EMT). In accord with this, we found systems-level indications for TGF-beta -driven EMT as one source of IPF myofibroblasts.

Conclusions: These findings establish the power of systems level genome-wide analysis to provide mechanistic insights into fibrotic disorders such as IPF. Our data point to derangements of translational control downstream of aberrant beta 1 integrin signaling as a fundamental component of IPF pathobiology and indicates that TGF-beta -driven EMT is one source for IPF myofibroblasts.

Citing Articles

Dysregulated bidirectional epithelial-mesenchymal crosstalk: a core determinant of lung fibrosis progression.

Yao L, Xu Z, Davies D, Jones M, Wang Y Chin Med J Pulm Crit Care Med. 2024; 2(1):27-33.

PMID: 38558961 PMC: 7615773. DOI: 10.1016/j.pccm.2024.02.001.


The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment.

Bartish M, Abraham M, Goncalves C, Larsson O, Rolny C, del Rincon S Nat Rev Cancer. 2023; 23(6):408-425.

PMID: 37142795 DOI: 10.1038/s41568-023-00567-5.


Early events marking lung fibroblast transition to profibrotic state in idiopathic pulmonary fibrosis.

Jia M, Rosas L, Kapetanaki M, Tabib T, Sebrat J, Cruz T Respir Res. 2023; 24(1):116.

PMID: 37085855 PMC: 10122312. DOI: 10.1186/s12931-023-02419-0.


Candida albicans-induced activation of the TGF-β/Smad pathway and upregulation of IL-6 may contribute to intrauterine adhesion.

Zhao X, Sun D, Zhang A, Huang H, Li Y, Xu D Sci Rep. 2023; 13(1):579.

PMID: 36631456 PMC: 9834405. DOI: 10.1038/s41598-022-25471-0.


Iron-Dependent Mitochondrial Dysfunction Contributes to the Pathogenesis of Pulmonary Fibrosis.

Takahashi M, Mizumura K, Gon Y, Shimizu T, Kozu Y, Shikano S Front Pharmacol. 2022; 12:643980.

PMID: 35058772 PMC: 8765595. DOI: 10.3389/fphar.2021.643980.


References
1.
Chilosi M, Zamo A, Doglioni C, Reghellin D, Lestani M, Montagna L . Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res. 2006; 7:95. PMC: 1538593. DOI: 10.1186/1465-9921-7-95. View

2.
Grinnell F . Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994; 124(4):401-4. PMC: 2119916. DOI: 10.1083/jcb.124.4.401. View

3.
Enomoto N, Suda T, Kato M, Kaida Y, Nakamura Y, Imokawa S . Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest. 2006; 130(1):22-9. DOI: 10.1378/chest.130.1.22. View

4.
Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H . Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2005; 171(11):1279-85. DOI: 10.1164/rccm.200404-531OC. View

5.
Moodley Y, Caterina P, Scaffidi A, Misso N, Papadimitriou J, McAnulty R . Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis. J Pathol. 2004; 202(4):486-95. DOI: 10.1002/path.1531. View